1. Scrip
  2. >>Business

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

Amondys 45 Gets DMD Nod From FDA

 
• By Alaric DeArment

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Sarepta's Amondys 45 won accelerated FDA approval for DMD patients ameable to exon 45 skipping • Source: Shutterstock

Sarepta Therapeutics, Inc. gained another inch with the US Food and Drug Administration approval of its third drug for Duchenne muscular dystrophy, but the mile ahead may come in the form of next-generation therapies for DMD. For some of them, data could emerge even before confirmatory data arrives for the company’s approved first-generation drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Regeneron To Expand US Manufacturing, Citing Commercial And Clinical Expansion

 
• By Alaric DeArment

The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.

Enzene To Add US Capacity Amid Tariff Talk

 
• By Vibha Ravi

Enzene Biosciences is likely to front-load capacity at its new US facility amid an onshoring focus, CEO Himanshu Gadgil tells Scrip. Possible US tariff exemption for Indian pharma products, impact of higher steel and aluminum tariffs on US manufacturing and a change in the company’s biosimilars strategy are discussed in this wide-ranging interview

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

 
• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.

More from Scrip

Stock Watch: Dollar Weakness, Tariffs, Biosimilars In J&J’s Q1 Mix

 
• By Andy Smith

Announcing increased full-year earnings guidance and another dividend increase, Johnson & Johnson’s stock price weakened, outweighed by concerns about the replacement of Stelara revenues and possible drug import tariffs.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Roche US Exports To Exceed Imports After New $50bn Investment

 
• By Andrew McConaghie

A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.